The novel therapeutic development targeting KRAS-mutant cancers also works on discovery of pan-Kras inhibitors and proteolysis targeting chimeras (PROTAC) which avoid HRAS and NRAS [55,56]. This evidence concerns the gene HRAS and cancer.